Skip to main content
Premium Trial:

Request an Annual Quote

Cellumen to Build CHDI-funded Systems Cell Biology Model of Huntington s Disease

NEW YORK, Feb.24 (GenomeWeb News) - In an agreement with non-profit CHDI, Cellumen will build a cellular model of Huntington's disease as the foundation of neurotoxicity profiling panel to characterize pre-clinical candidate models, Cellumen said yesterday.

The collaboration is expected to last about a year, Robert Pacifici of CHDI told GenomeWeb News.

"Cell-based phenotypic assays are critical for CHDI since there is not a clearly defined set of well-validated and chemically tractable targets for HD drug discovery," said Pacifici.

CHDI is the non-profit drug-discovery arm of the High Q Foundation for Huntington's disease.

Financial details were not released.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.